Statin Use for the Primary Prevention of Cardiovascular Disease in Adults
Применение статинов для первичной профилактики сердечно-сосудистых заболеваний у взрослых
2022-08-23
SCID: 54.1/an5qk382
Discuss with AI
10-year CVD riskUSPSTF recommendationscardiovascular diseaseprimary preventionstatin therapy
Figures from the paper
Abstract (AI)
Importance: Cardiovascular disease (CVD) is the leading cause of morbidity and death in the US and is the cause of more than 1 of every 4 deaths. Coronary heart disease is the single leading cause of death and accounts for 43% of deaths attributable to CVD in the US. In 2019, an estimated 558 000 deaths were caused by coronary heart disease and 109 000 deaths were caused by ischemic stroke. Objective: To update its 2016 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a review of the evidence on the benefits and harms of statins for reducing CVD-related morbidity or mortality or all-cause mortality. Population: Adults 40 years or older without a history of known CVD and who do not have signs and symptoms of CVD. Evidence Assessment: The USPSTF concludes with moderate certainty that statin use for the prevention of CVD events and all-cause mortality in adults aged 40 to 75 years with no history of CVD and who have 1 or more CVD risk factors (ie, dyslipidemia, diabetes, hypertension, or smoking) and an estimated 10-year CVD event risk of 10% or greater has at least a moderate net benefit. The USPSTF concludes with moderate certainty that statin use for the prevention of CVD events and all-cause mortality in adults aged 40 to 75 years with no history of CVD and who have 1 or more of these CVD risk factors and an estimated 10-year CVD event risk of 7.5% to less than 10% has at least a small net benefit. The USPSTF concludes that the evidence is insufficient to determine the balance of benefits and harms of statin use for the primary prevention of CVD events and mortality in adults 76 years or older with no history of CVD. Recommendation: The USPSTF recommends that clinicians prescribe a statin for the primary prevention of CVD for adults aged 40 to 75 years who have 1 or more CVD risk factors (ie, dyslipidemia, diabetes, hypertension, or smoking) and an estimated 10-year CVD risk of 10% or greater. (B recommendation) The USPSTF recommends that clinicians selectively offer a statin for the primary prevention of CVD for adults aged 40 to 75 years who have 1 or more of these CVD risk factors and an estimated 10-year CVD risk of 7.5% to less than 10%. The likelihood of benefit is smaller in this group than in persons with a 10-year risk of 10% or greater. (C recommendation) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of initiating a statin for the primary prevention of CVD events and mortality in adults 76 years or older. (I statement).
Key Findings
1
Evidence is insufficient to determine the balance of benefits and harms of statins for primary prevention in adults aged 76 years or older without known cardiovascular disease.
2
Relevant cardiovascular risk factors are dyslipidemia, diabetes, hypertension, and smoking in adults without established cardiovascular disease.
3
Statin use provides at least a moderate net benefit for preventing cardiovascular events and all-cause mortality in adults aged 40–75 years with cardiovascular risk factors and 10-year risk of 10% or greater.
4
Statin use provides at least a small net benefit for adults aged 40–75 years with at least one cardiovascular risk factor and estimated 10-year risk of 7.5% to less than 10%.
5
The USPSTF recommends prescribing statins to eligible adults aged 40–75 years with at least one risk factor and a 10-year cardiovascular risk of 10% or greater.
Research Object
Adults aged 40 years or older without known cardiovascular disease, evaluated for primary-prevention statin use
Research Subject
Benefits, harms, and net benefit of statin use for preventing cardiovascular events and all-cause mortality according to cardiovascular risk
Publication Details
Publication Date
2022-08-23
Journal
Publisher
ISSN
Cited by
391
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai2
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines2019
Statin Use for the Primary Prevention of Cardiovascular Disease in Adults2022